TopBP1 Mediates Mutant p53 Gain of Function through NF-Y and p63/p73
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Nearly half of human cancers harbor p53 mutations, which can promote cancerous growth, metastasis, and resistance to therapy. The gain of function of mutant p53 is partly mediated by its ability to form a complex with NF-Y or p63/p73. Here, we demonstrate that TopBP1 mediates these activities in cancer, and we provide both in vitro and in vivo evidence to support its role. We show that TopBP1 interacts with p53 hot spot mutants and NF-YA and promotes mutant p53 and p300 recruitment to NF-Y target gene promoters. TopBP1 also facilitates mutant p53 interaction with and inhibition of the transcriptional activities of p63/p73. Depletion of TopBP1 in mutant p53 cancer cells leads to downregulation of NF-Y target genes cyclin A and Cdk1 and upregulation of p63/p73 target genes such as Bax and Noxa. Mutant p53-mediated resistance to chemotherapeutic agents depends on TopBP1. The growth-promoting activity of mutant p53 in a xenograft model also requires TopBP1. Thus, TopBP1 mediates mutant p53 gain of function in cancer. Since TopBP1 is often overexpressed in cancer cells and is recruited to cooperate with mutant p53 for tumor progression, TopBP1/mutant p53 interaction may be a new therapeutic target in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, Y., Rayman, J. B., & Dynlacht, B. D. (2000) · Genes & Development · doi:10.1101/gad.14.7.804 · Cited by 621
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418 · cited 4×
“It has been shown that the induction of NF-Y target genes, such as cyclin A, cyclin B, and Cdk1 by DNA-damaging agents in mutp53-harboring cancer cells is dependent on mutp53 (7).”
BackgroundMethodInfluentialBACH1/FANCJ Acts with TopBP1 and Participates Early in DNA Replication Checkpoint Control
Gong, Z., Kim, J.-E., Leung, C. C. Y., Glover, J. N. M., & Chen, J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.002 · Cited by 160 · cited 1×
“The sensing step is followed by an interaction with a DNA helicase, BACH1, which might facilitate the unwinding of double-stranded DNA for an additional replication protein A (RPA) coating, and subsequent loading of ATR/ATRIP and the 9-1-1 complex (14).”
BackgroundIdentification and functional analysis of TopBP1 and its homologs
Garcia, V., Furuya, K., & Carr, A. M. (2005) · DNA Repair · doi:10.1016/j.dnarep.2005.04.001 · Cited by 158
MDC1 collaborates with TopBP1 in DNA replication checkpoint control
Wang, J., Gong, Z., & Chen, J. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201010026 · Cited by 118 · cited 1×
“Recruitment of TopBP1 to double-strand breaks or stalled replication forks was recently shown to be dependent on its interaction with 53BP1 (4) or MDC1 (43).”
BackgroundTopBP1 and DNA polymerase-α directly recruit the 9-1-1 complex to stalled DNA replication forks
Yan, S., & Michael, W. M. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200810185 · Cited by 107
Yan, S., & Michael, W. M. (2009) · Cell Cycle · doi:10.4161/cc.8.18.9485 · Cited by 72 · cited 1×
“Their data suggest a role of replication stress sensor for TopBP1 (46, 47).”
BackgroundKarppinen, S.-M., Erkko, H., Reini, K., Pospiech, H., Heikkinen, K., Rapakko, K., Syväoja, J. E., & Winqvist, R. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.030 · Cited by 42 · cited 1×
“With a report that a missense variant (R309C) occurred at an elevated frequency in familial breast cancer cases compared to healthy controls from Finland (22), TopBP1 has been suggested as a breast cancer susceptibility gene.”
BackgroundAberrant expression of TopBP1 in breast cancer
Going, J. J., Nixon, C., Dornan, E. S., Boner, W., Donaldson, M. M., & Morgan, I. M. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02622.x · Cited by 35
Cited by
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
“…et al., 2002; Kawamata et al., 2007; Tsang et al., 2005; Wong et al., 2007 R175H, R248W, R273H SKOV-3 stable/transient Buganim et al., 2006; Liu et al., 2011; Pugacheva et al., 2002 R175H, R248W, R273H H1299 stable/ transient Blandino et al., 1999; Di Como et al., 1999; Pugacheva et al.,…”
BackgroundInfluentialUnravelling mechanisms of p53-mediated tumour suppression
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3711 · Cited by 1,387
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
Mutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775
p53 signaling in cancer progression and therapy
Marei, H. E., Althani, A., Afifi, N., Hasan, A., Caceci, T., Pozzoli, G., Morrione, A., Giordano, A., & Cenciarelli, C. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02396-8 · Cited by 588
Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P., Wagenblast, E., Davis, C. A., Moon, S.-H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.066 · Cited by 466
“The discrepancy could reflect different extraction conditions or biological settings, because the mutant p53/NF-Y interaction has been shown to occur upon DNA damage (Liu et al., 2011).”
The Role of p53 Signaling in Colorectal Cancer
Liebl, M. C., & Hofmann, T. G. (2021) · Cancers · doi:10.3390/cancers13092125 · Cited by 318
Kim, M. P., & Lozano, G. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.185 · Cited by 311
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Walerych, D., Napoli, M., Collavin, L., & Del Sal, G. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 289
Mutant p53 in Cancer Progression and Targeted Therapies
Zhu, G., Pan, C., Bei, J.-X., Li, B., Liang, C., Xu, Y., & Fu, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.595187 · Cited by 218
Ding, D., Blee, A. M., Zhang, J., Pan, Y., Becker, N. A., Maher, L. J., Jimenez, R., Wang, L., & Huang, H. (2023) · Nature Communications · doi:10.1038/s41467-023-40352-4 · Cited by 27
Metadata
- Authors
- Liu, K., Ling, S., & Lin, W.-C.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2011-11-01
- Volume
- 31
- Issue
- 22
- Pages
- 4464-4481
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2119413661
- Cited by
- 122
- References
- 10
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.